TCGA-A8-A07L-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 32
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- G2M_CHECKPOINT+0.510
- MYC_TARGETS_V1+0.490
- MYC_TARGETS_V2+0.460
- MITOTIC_SPINDLE+0.340
- DNA_REPAIR+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MTORC1_SIGNALING+0.200
- OXIDATIVE_PHOSPHORYLATION+0.170
- WNT_BETA_CATENIN_SIGNALING+0.170
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- INTERFERON_GAMMA_RESPONSE-0.440
- INFLAMMATORY_RESPONSE-0.420
- IL6_JAK_STAT3_SIGNALING-0.410
- KRAS_SIGNALING_UP-0.400
- INTERFERON_ALPHA_RESPONSE-0.380
- COAGULATION-0.340
- COMPLEMENT-0.310
- FATTY_ACID_METABOLISM-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1194 | — | — | 0.919 |
| 2 | CA366342-0949-4941-8AE6-984BAF032886 | — | — | 0.915 |
| 3 | SRR8526717 | — | cohortMD1 | 0.912 |
| 4 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.909 |
| 5 | SRR12696755 | — | — | 0.908 |
| 6 | BS_MDBT7S5Z | high-grade glioma | — | 0.908 |
| 7 | ERR2598206 | fetal | fetal | 0.901 |
| 8 | BS_N6N147BY | Embryonal tumors | — | 0.901 |
| 9 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.900 |
| 10 | TCGA-BL-A3JM-01A-12R-A21D-07 | — | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |